• Cy5-UTP: Five Questions for Better RNA Interpretation

  2026-10-08

  Cy5-UTP enables direct fluorescent RNA labeling, but fluorescence should be interpreted as an analytical readout rather than proof of RNA function or delivery. This overview separates supplier claims from published evidence and explains what recent lung-targeted mRNA nanoparticle research can—and cannot—establish about labeled RNA.

• Recombinant Human IL-15: Evidence and Context

  2026-10-08

  This overview places Recombinant Human IL-15 in the context of cytokine biology, immune-cell research, and emerging RNA-based genome editing. It separates supplier-reported product characteristics from findings in the CREATE study and explains the limits of applying evidence across these distinct research areas.

• PTEN mRNA Delivery and Trastuzumab Resistance

  2026-10-07

  Dong and colleagues developed a tumor-microenvironment-responsive nanoparticle system for systemic PTEN mRNA delivery and reported restoration of PTEN signaling control in trastuzumab-resistant breast cancer models. The study is important because it links delivery design with a resistance mechanism, while its formulation-specific, preclinical evidence should not be generalized directly to other mRNA materials or clinical treatment.

• DiscoveryProbe Protease Inhibitor Library: Evidence

  2026-10-07

  The DiscoveryProbe Protease Inhibitor Library is examined through an evidence-centered framework for protease inhibition, linking biochemical screening, cell biology, and chemical-quality interpretation. This perspective clarifies what an 825-compound collection can reveal, what it cannot establish alone, and how the findings relate to modern virtual-screening standards.

• Patient-Derived Spheroids in Organ-Confined Prostate Cancer

  2026-10-06

  Linxweiler and colleagues established viable, patient-derived three-dimensional spheroids from radical prostatectomy specimens, addressing a major gap in models of organ-confined prostate cancer. The study supports spheroids as a translational platform for biomarker characterization, cryopreservation, and comparative drug-response research, while also showing that treatment findings require careful interpretation of tissue context and compound identity.

• Hyperthermia, Cisplatin, and Caspase-8-Driven Cell Death

  2026-10-06

  A 2024 study reports that combining hyperthermia with cisplatin increases caspase-8 accumulation and activation, linking ubiquitination, apoptosis, and pyroptosis in cancer-cell models. The findings provide a mechanistic framework for interpreting caspase activity measurement while also showing why caspase-3 readouts should be integrated with pathway-specific and cell-death evidence.

• Cy5-UTP for Interpreting mRNA Delivery

  2026-10-05

  Cy5-UTP enables fluorescent RNA tracking, but its greatest value may be interpretive: separating cargo localization, intracellular delivery, and biological activity. This article examines how Cyanine 5-uridine triphosphate could contextualize mRNA–LNP studies without overstating what fluorescence proves.

• Spiroplasma Entry into Drosophila S2 Cells

  2026-10-05

  Wei and colleagues established a Drosophila Schneider 2 cell model showing that Spiroplasma eriocheiris can enter insect cells, proliferate intracellularly, and induce substantial cellular injury. Pharmacological and cytoskeletal evidence linked entry primarily to clathrin-mediated endocytosis and macropinocytosis, while also defining important limits for interpreting inhibitor-based pathway studies.

• PSMD14–CARM1 Signaling in Hepatocellular Carcinoma

  2026-10-04

  A 2025 Cell Death and Disease study identifies a PSMD14–CARM1–FERMT1 axis that links deubiquitination, histone arginine methylation, and hepatocellular carcinoma progression. The findings support CARM1 as a mechanistically relevant therapeutic target, while remaining preclinical and dependent on validation beyond the reported models.

• FAISL, FAK, and TNBC Metastasis: Study Analysis

  2026-10-03

  A 2024 Advanced Science study identifies FAISL as a long noncoding RNA that stabilizes focal adhesion kinase by limiting Calpain 2-mediated proteolysis. The work connects lncRNA-dependent protein regulation with triple negative breast cancer progression and provides a preclinical rationale for studying FAISL as a disease-associated regulator, while leaving clinical applicability and broader pathway transferability unresolved.

• Cell and Reporter Effects in mRNA-LNP Assays

  2026-10-02

  Zhen et al. show that cell-line choice and reporter identity can substantially alter apparent mRNA-LNP transfection performance. HEK 293T cells produced the strongest luciferase dose response, whereas eGFP provided more reproducible quantitative measurements, highlighting the need to validate assay biology and readout technology together.

• Full-Length αvβ3 Integrin Dynamics by Cryo-EM

  2026-10-01

  A 2026 cryo-EM study resolves six apo and five ligand-bound conformations of full-length human αvβ3 integrin, revealing a continuous structural landscape rather than a simple inactive-to-active switch. Its observation that CWHM-12 can stabilize coexisting closing and opening inhibited states provides a mechanistic basis for designing more selective integrin inhibitors.

• Targeted BRD7 Demethylation in Nasopharyngeal Carcinoma

  2026-10-01

  Wei and colleagues developed a CRISPR/dCas9-TET1 catalytic-domain system to demethylate the BRD7 promoter and restore expression in nasopharyngeal carcinoma models. The study links locus-specific epigenetic editing with reduced malignant progression and provides a framework for distinguishing targeted tumor suppressor gene reactivation from broader DNA hypomethylation strategies.

• Caspase-3 Fluorometric Assay Kit: Causal Readout

  2026-09-30

  The Caspase-3 Fluorometric Assay Kit provides a quantitative DEVD-dependent readout for distinguishing executioner-caspase activation from broader cell-death phenotypes. This article develops an assay interpretation framework grounded in recent evidence for ferroptosis–apoptosis crosstalk, emphasizing controls, timing, and orthogonal validation.

• Chlorpromazine HCl for Reliable Cell Assays

  2026-09-30

  This scenario-driven guide shows how Chlorpromazine HCl (SKU B1480) can improve interpretation and workflow control in cell viability, proliferation, cytotoxicity, and neuropharmacology studies. It covers mechanism-aware controls, formulation, dose selection, data interpretation, and practical supplier evaluation.

8120 records 1/542 page Next 12345 下5页 Last page